FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2576174906> ?p ?o ?g. }

• W2576174906 abstract "Abstract Abstract 2780 Poster Board II-756 Patients with refractory anemia with ring sideroblasts (RARS) are considered to have good prognosis and anemia is usually managed with best supportive care and erythroid stimulating agents. Nowadays, no specific molecular marker related to outcome and disease progression has been identified. Several genes involved in cell cycle and apoptosis that may become inactivated by aberrant hypermethylation have been identified in patients with myelodysplastic syndromes (MDS) but the significance of a methylation profile (studying several genes at the same time) in RARS is unknown, mainly because the number of patients with RARS in published reports is rather low. To assess the implication of aberrant methylation in RARS, we studied the methylation status of 25 sequences of a set of tumor suppressor genes in 40 patients (median age 70 yr, 25 male gender) with RARS according to FAB criteria [WHO classification, RARS in 22 patients (55%); refractory citopenia with multilineage dysplasia and ring sideroblasts, 18 (45%)] by means of methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. The MS-MLPA procedure (SALSA MLPA kit ME001, MRC-Holland, Amsterdam, The Netherlands) has been developed for detecting in a semi-quantitative manner changes in the methylation status of 25 tumor suppressor genes in a single experiment. Briefly, approximately 50 ng of DNA were denatured and hybridized with MLPA probes. Subsequently, the probes were ligated in half of every sample, whereas for the rest of the sample, ligation was combined with an endonuclease HhaI digestion resulting in ligation of the methylated sequences only. PCR was performed as described by the manufacturer, and then separated by capillary gel electrophoresis and quantified using the Genemapper software (ABI 310, Applied Biosystems, Foster City, CA). Quantification of the methylation status was done by dividing the peak area with the combined areas of the control probes lacking the target sequence of the HhaI. Finally, the relative peak area of each target probe from the digested sample was compared with those obtained from the undigested sample. Aberrant methylation was scored when the calculated methylation percentage was >10%. To validate the MS-MLPA method the methylation status of CDKN2B was also analyzed by methylation-specific PCR (MSP). Actuarial curves of OS were built by Kaplan-Meier method and differences between curves compared with log-rank tests. Small numbers precluded the use of multivariate methodology. The MS-MLPA analysis detected methylation of at least one gene in 17 patients (42.5%). The genes aberrantly methylated were CDKN2B (n = 8, 20%), RASSF1 (n = 7, 17%), RARB (n = 3, 7.5%), CDH13 (n = 3, 7.5%) and FHIT (n = 2; 5%). Of the 17 patients, five (12%) presented methylation in two genes (RASSF1-FHIT in 2, RASSF1-RARB in 1, RASSF1-CDH13 in 1, and CDKN2B-CDH13 in 1, who was the only patient who progressed to AML). The presence of aberrant gene methylation was not significantly associated with any clinical or biological characteristic or WHO morphological subtype. Patients with aberrant gene methylation had a significantly shorter overall survival (OS) than patients without methylated genes (median OS, 72 mo vs 114 mo, respectively; P = 0.03). Patients with hemoglobin level below 10 g/dL and platelet count below 150 ×109/L also had a significantly poorer OS (P= 0.01 and P= 0.02, respectively). As the majority of probes used in the MS-MPLA method detect methylation in only one CpG pair, the results of CDKN2B methylation were validated by MSP, which yielded the same methylation results than with MS-MPLA methodology. The 8 patients with methylated CDKN2B show a trend for a shorter survival than the remaining 32 with unmethylated CDKN2B (median 72 mo vs 114 mo, P = 0.08). The results of this study indicate that aberrant methylation of several tumor suppressor genes is observed in a substantial proportion of patients with RARS. As occurs in patients with high-risk MDS, our results suggest that aberrant gene methylation confers a poor prognosis in RARS, but these data and their potential independent value require confirmation in larger series that employ multivariate methods. Finally, these findings provide a strong rationale for the use of hypomethylating agents (e.g., azacitidine or decitabine) in patients with RARS. This work has been partially supported by ISCIII grants RD06/0020/0031 and CA08/00141. Disclosures: No relevant conflicts of interest to declare." @default.
• W2576174906 created "2017-01-26" @default.
• W2576174906 creator A5008789956 @default.
• W2576174906 creator A5009781859 @default.
• W2576174906 creator A5017341923 @default.
• W2576174906 creator A5030067333 @default.
• W2576174906 creator A5036151198 @default.
• W2576174906 creator A5036479415 @default.
• W2576174906 creator A5038326685 @default.
• W2576174906 creator A5052934298 @default.
• W2576174906 creator A5066552050 @default.
• W2576174906 creator A5068275399 @default.
• W2576174906 creator A5081599372 @default.
• W2576174906 creator A5088719838 @default.
• W2576174906 date "2009-11-20" @default.
• W2576174906 modified "2023-09-27" @default.
• W2576174906 title "A Methylation Profile of Tumor Suppressor Genes Predicts a Poorer Survival in Patients with Refractory Anemia with Ringed Sideroblasts." @default.
• W2576174906 doi "https://doi.org/10.1182/blood.v114.22.2780.2780" @default.
• W2576174906 hasPublicationYear "2009" @default.
• W2576174906 type Work @default.
• W2576174906 sameAs 2576174906 @default.
• W2576174906 citedByCount "0" @default.
• W2576174906 crossrefType "journal-article" @default.
• W2576174906 hasAuthorship W2576174906A5008789956 @default.
• W2576174906 hasAuthorship W2576174906A5009781859 @default.
• W2576174906 hasAuthorship W2576174906A5017341923 @default.
• W2576174906 hasAuthorship W2576174906A5030067333 @default.
• W2576174906 hasAuthorship W2576174906A5036151198 @default.
• W2576174906 hasAuthorship W2576174906A5036479415 @default.
• W2576174906 hasAuthorship W2576174906A5038326685 @default.
• W2576174906 hasAuthorship W2576174906A5052934298 @default.
• W2576174906 hasAuthorship W2576174906A5066552050 @default.
• W2576174906 hasAuthorship W2576174906A5068275399 @default.
• W2576174906 hasAuthorship W2576174906A5081599372 @default.
• W2576174906 hasAuthorship W2576174906A5088719838 @default.
• W2576174906 hasConcept C104317684 @default.
• W2576174906 hasConcept C120599132 @default.
• W2576174906 hasConcept C126322002 @default.
• W2576174906 hasConcept C150194340 @default.
• W2576174906 hasConcept C153911025 @default.
• W2576174906 hasConcept C190727270 @default.
• W2576174906 hasConcept C203014093 @default.
• W2576174906 hasConcept C2780007613 @default.
• W2576174906 hasConcept C2780817109 @default.
• W2576174906 hasConcept C2781188995 @default.
• W2576174906 hasConcept C33288867 @default.
• W2576174906 hasConcept C36823959 @default.
• W2576174906 hasConcept C502942594 @default.
• W2576174906 hasConcept C54355233 @default.
• W2576174906 hasConcept C71924100 @default.
• W2576174906 hasConcept C86803240 @default.
• W2576174906 hasConceptScore W2576174906C104317684 @default.
• W2576174906 hasConceptScore W2576174906C120599132 @default.
• W2576174906 hasConceptScore W2576174906C126322002 @default.
• W2576174906 hasConceptScore W2576174906C150194340 @default.
• W2576174906 hasConceptScore W2576174906C153911025 @default.
• W2576174906 hasConceptScore W2576174906C190727270 @default.
• W2576174906 hasConceptScore W2576174906C203014093 @default.
• W2576174906 hasConceptScore W2576174906C2780007613 @default.
• W2576174906 hasConceptScore W2576174906C2780817109 @default.
• W2576174906 hasConceptScore W2576174906C2781188995 @default.
• W2576174906 hasConceptScore W2576174906C33288867 @default.
• W2576174906 hasConceptScore W2576174906C36823959 @default.
• W2576174906 hasConceptScore W2576174906C502942594 @default.
• W2576174906 hasConceptScore W2576174906C54355233 @default.
• W2576174906 hasConceptScore W2576174906C71924100 @default.
• W2576174906 hasConceptScore W2576174906C86803240 @default.
• W2576174906 hasLocation W25761749061 @default.
• W2576174906 hasOpenAccess W2576174906 @default.
• W2576174906 hasPrimaryLocation W25761749061 @default.
• W2576174906 hasRelatedWork W138215648 @default.
• W2576174906 hasRelatedWork W1972578692 @default.
• W2576174906 hasRelatedWork W1990763586 @default.
• W2576174906 hasRelatedWork W2015638273 @default.
• W2576174906 hasRelatedWork W2033453412 @default.
• W2576174906 hasRelatedWork W2053256886 @default.
• W2576174906 hasRelatedWork W2171134090 @default.
• W2576174906 hasRelatedWork W2188228334 @default.
• W2576174906 hasRelatedWork W2407992780 @default.
• W2576174906 hasRelatedWork W2531490992 @default.
• W2576174906 hasRelatedWork W2538802494 @default.
• W2576174906 hasRelatedWork W2564104539 @default.
• W2576174906 hasRelatedWork W2564517427 @default.
• W2576174906 hasRelatedWork W2579985658 @default.
• W2576174906 hasRelatedWork W2583715705 @default.
• W2576174906 hasRelatedWork W2751769043 @default.
• W2576174906 hasRelatedWork W2979666935 @default.
• W2576174906 hasRelatedWork W2980236019 @default.
• W2576174906 hasRelatedWork W2992053863 @default.
• W2576174906 hasRelatedWork W2019314492 @default.
• W2576174906 isParatext "false" @default.
• W2576174906 isRetracted "false" @default.
• W2576174906 magId "2576174906" @default.
• W2576174906 workType "article" @default.